Kairos Pharma LTD

Kairos Pharma addresses a critical challenge in oncology: drug resistance, a major factor in cancer relapse and poor outcomes, contributing to up to 90% of treatment failures. Unlike traditional approaches that develop new drugs after therapies fail, Kairos directly targets resistance mechanisms and restores the effectiveness of frontline therapies. This approach reduces treatment failures, extends the duration of response, and improves treatment for patients.